NASDAQ · ENGN
Healthcare · Biotechnology
$1.67
Down-$0.04 (-2.34%)
Updated Oct 18, 2026, 12:04 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ENGN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
ENGN closed at $1.67 after 20 trading sessions, down 14.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $1.73 | $1.7489 | $1.65 | $1.67 | 1.16M |
| Oct 15, 2026 | $1.61 | $1.735 | $1.58 | $1.71 | 1.18M |
| Oct 14, 2026 | $1.60 | $1.62 | $1.56 | $1.56 | 943.53K |
| Oct 13, 2026 | $1.69 | $1.70 | $1.62 | $1.63 | 914.09K |
| Oct 12, 2026 | $1.73 | $1.74 | $1.69 | $1.70 | 462.72K |
| Oct 9, 2026 | $1.76 | $1.81 | $1.7201 | $1.73 | 359.13K |
| Oct 8, 2026 | $1.75 | $1.79 | $1.68 | $1.78 | 1.46M |
| Oct 7, 2026 | $1.80 | $1.859 | $1.74 | $1.745 | 708.29K |
| Oct 6, 2026 | $1.87 | $1.87 | $1.80 | $1.80 | 361.66K |
| Oct 5, 2026 | $1.94 | $1.94 | $1.785 | $1.87 | 952.87K |
| Oct 2, 2026 | $2.00 | $2.02 | $1.93 | $1.94 | 692.75K |
| Oct 1, 2026 | $2.01 | $2.01 | $1.96 | $1.98 | 903.04K |
| Sep 30, 2026 | $1.965 | $2.02 | $1.93 | $2.00 | 1.28M |
| Sep 29, 2026 | $1.97 | $1.97 | $1.915 | $1.95 | 393.18K |
| Sep 28, 2026 | $1.96 | $1.98 | $1.90 | $1.97 | 332.19K |
| Sep 25, 2026 | $1.94 | $1.9691 | $1.875 | $1.96 | 1.98M |
| Sep 24, 2026 | $1.99 | $1.99 | $1.905 | $1.92 | 796.3K |
| Sep 23, 2026 | $2.05 | $2.05 | $1.98 | $2.00 | 669.46K |
| Sep 22, 2026 | $1.96 | $2.08 | $1.96 | $2.05 | 1.07M |
| Sep 21, 2026 | $1.92 | $1.97 | $1.90 | $1.96 | 426.34K |
The latest Smart Investors Daily articles mentioning ENGN.
Company
Market Activity
Research & News
ENGN research
Company profile and research snapshot.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Perform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Morgan Stanley | Underweight | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
enGene Therapeutics trades below cash value. Read on to assess risks, cost cuts extending the runway to 2029, and the potential upside to a $6.65 fair value.
Benzinga · Sep 9, 2026
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
Benzinga · Sep 8, 2026
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from
Yahoo · Aug 4, 2026
BOSTON & MONTREAL, August 04, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dri
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENGN.
